News

Albemarle High School Teen Competes for Virginia

Virginia Bio and the Virginia Bioscience Foundation have named Albemarle High School’s, Meenakshi “Meena” Ambati, as the winner of the 2021 Virginia BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field. As the Virginia BioGENEius finalist, Meena will attend the 2021 BIO Digital Conference, where she will engage with leading companies, scientists and innovators currently transforming the scientific landscape in order to gain invaluable insights into an industry making significant contributions to the world.

Meena’s project was titled “Identification of Fluoxetine as a direct NLRP3 inhibitor to treat atrophic macular degeneration: Molecular modeling, Mechanism, Morphometry, and Meta-analysis (Year 2)”. The project was selected by an independent panel of volunteer judges representing the Virginia Bio membership.

Recent News

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …

11/04/2026

$6 Million in Philanthropic Gifts Establishes UVA Biotech Innovation Fund

The University of Virginia Paul and Diane Manning Institute of Biotechnology received gifts totaling $6 million from philanthropists to establish the UVA Biotech Innovation Fund. This fund will provide long-term support for the UVA SPARK Innovative Medicines program, helping accelerate promising discoveries toward new treatments and cures. “The mission of the UVA Manning Institute of …

10/29/2026

ReAlta Life Sciences Launches KnowHIE, a New Online Educational Resource for Families of Babies Diagnosed with Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the launch of KnowHIE.com, a new educational website designed to help families and caregivers better understand neonatal hypoxic ischemic encephalopathy (HIE) …